Svas Biosana’s Strategic Growth and Strong Financial Performance Justify Buy Rating

Davide Longo, an analyst from TP ICAP MIDCAP, reiterated the Buy rating on Svas Biosana S.p.A. (SVS – Research Report). The associated price target remains the same with €12.40.

Davide Longo has given his Buy rating due to a combination of factors that highlight Svas Biosana’s strong financial performance and strategic growth initiatives. The company reported a significant increase in revenue for the first quarter of 2025, driven by recent acquisitions and robust market presence in the Balkans. The integration of Mark Medical and Bormia has been successful, contributing to the company’s growth momentum, while the Medical division has shown a notable rebound due to a revamped commercial strategy.
Additionally, the company’s expansion strategy in Eastern Europe, particularly through targeted acquisitions, has proven effective, enhancing its market position. Despite challenges such as raw material cost pressures, Svas Biosana’s divisions like Farmex have demonstrated resilience. The stock is considered undervalued, trading at a low price-to-earnings ratio, which, combined with a strong return on capital employed and recovery in distribution activities in Italy, supports the Buy rating with a target price of €12.4.

SVS’s price has also changed moderately for the past six months – from EUR6.800 to EUR7.820, which is a 15.00% increase.